Long-term benefits in COMBI-AD
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-018-0122-z
Abstract: initial data from the COMBi-aD trial suggested promising benefits of adjuvant dabrafenib plus trametinib (D + t) for patients with high-risk, stage iii, BRAF-mutant melanoma. Now, extended follow-up data from the trial confirm these benefits.… read more here.
Keywords: term benefits; long term; group; low tmb ... See more keywords